Aug 4, 2025 04:31PM
May 23, 2025 04:52PM
May 15, 2025 06:00AM
May 7, 2025 08:45AM
May 7, 2025 08:45AM
Apr 22, 2025 07:41AM
Apr 22, 2025 07:40AM OS Therapies FDA Meeting Request Granted
Apr 9, 2025 07:40AM
Apr 9, 2025 07:40AM
Apr 7, 2025 06:00AM
Apr 2, 2025 07:40AM
Mar 31, 2025 07:40AM
Mar 31, 2025 07:40AM
Mar 25, 2025 07:40AM OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Mar 21, 2025 07:40AM
Mar 13, 2025 07:40AM
Mar 11, 2025 07:40AM
Feb 26, 2025 04:01PM
Feb 24, 2025 07:25AM
Feb 24, 2025 07:25AM
Feb 20, 2025 05:54AM OS Therapies (OSTX) Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Feb 20, 2025 05:00AM
Feb 14, 2025 07:36AM
Feb 14, 2025 07:36AM
Feb 4, 2025 07:33AM
Feb 4, 2025 07:33AM
Jan 31, 2025 04:22PM
Jan 29, 2025 09:22AM OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pip
Jan 15, 2025 07:45AM
Jan 15, 2025 07:40AM
Jan 3, 2025 05:28PM
Jan 2, 2025 11:16AM
Dec 31, 2024 03:38PM
Dec 31, 2024 03:38PM
Dec 26, 2024 12:30PM OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online
Dec 26, 2024 10:03AM
Dec 26, 2024 10:01AM
Dec 24, 2024 09:32AM
Dec 24, 2024 09:32AM
Nov 27, 2024 04:15PM
Nov 12, 2024 05:12PM
Nov 4, 2024 07:00AM OS Therapies to Present at The Spartan Capital Investor Conference
Oct 30, 2024 08:51AM
Oct 28, 2024 04:44PM
Oct 28, 2024 04:44PM
Oct 24, 2024 08:46AM
Oct 17, 2024 09:22AM
Oct 3, 2024 08:00AM
Sep 13, 2024 08:09AM OS Therapies (OSTX) Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Sep 13, 2024 08:09AM

64,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All